Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs

• Published in: Journal of hepato-biliary-pancreatic sciences Vol. 22; no. 8; pp. 618 - 622
• Main Authors: Igarashi, Hisato, Hijioka, Masayuki, Lee, Lingaku, Ito, Tetsuhide
• Format: Journal Article
• Language: English
• Published: Japan Blackwell Publishing Ltd 01.08.2015; Wiley Subscription Services, Inc
• Subjects: Biological Therapy - methods; Female; Humans; Lanreotide; Male; Middle Aged; Neuroendocrine Tumors - drug therapy; Octreotide; Pancreatic Neoplasms - drug therapy; Pancreatic neuroendocrine tumors; Somatostatin - therapeutic use; Somatostatin analog; Tumors; Pancreatic neuroendocrine tumors; Octreotide; Lanreotide; Somatostatin analog
• ISSN: 1868-6974; 1868-6982
• DOI: 10.1002/jhbp.227

Basically, pancreatic neuroendocrine tumor (PNET) should be treated surgically; however, in unresectable cases, a treatment that aims to improve the prognosis by inhibiting the growth of the tumor and control the clinical symptoms becomes necessary. In the case of functional tumors, the quality of life of patients is decreased by not only the symptoms with tumor invasion and/or metastasis but also by the symptoms of hormone excess. The efficacy of somatostatin analogs against the latter has been previously reported, and their sustained release formulations have been developed. Somatostatin analogs are recommended to treat the endocrine symptoms of functional PNET; however, in case they can cause hypoglycemia in patients with insulinoma. On the other hand, results from the PROMID study demonstrated a tumor‐stabilizing effect when octreotide LAR (long acting repeatable) was used to treat patients with advanced midgut NET; however, there has been no consensus regarding its antitumor effect for PNET. Additionally, a recent result from the CLARINET study suggests that lanreotide autogel has an antitumor effect against nonfunctional NET including PNET. Further clinical study results are awaited.